All In Biotech

Drug Trial Radar · NCT02181413

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

656

Actual

Start

Jul 16, 2014

Primary completion

Apr 16, 2018

Study completion Sep 8, 2023

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

Conditions

  • Multiple Myeloma
  • Autologous Stem Cell Transplant

Interventions

  • Ixazomib CitrateDrug

    Ixazomib citrate capsules

  • PlaceboDrug

    Ixazomib citrate placebo-matching capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)

Locations

227 sites in 33 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • Montefiore Medical Center

    The Bronx, New York

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Baylor University Medical Center

    Dallas, Texas

  • West Virginia University Hospital

    Morgantown, West Virginia

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Iturraspe

    Santa Fe, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Instituto de Hematologia Y Medicina Clinica Dr Ruben Davoli

    Rosario, Santa Fe Province, Argentina

  • Sanatorio Britanico de Rosario

    Rosario, Santa Fe Province, Argentina

  • Sanatorio Parque de Rosario

    Rosario, Santa Fe Province, Argentina

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, Australia

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Elisabethinen Hospital Linz

    Linz, Austria

  • Salzburger Landeskliniken

    Salzburg, Austria

  • Allgemeines Krankenhaus der Stadt Wien

    Vienna, Austria

  • Klinik Ottakring (fruher: Wilhelminenspital)

    Vienna, Austria

  • ZNA Middelheim

    Antwerp, Belgium

  • ZNA Stuivenberg

    Antwerp, Belgium

  • Centre Hospitalier Jolimont-Lobbes

    La Louvière, Hainaut, Belgium

  • Centre Hospitalier Universitaire Ambroise Pare

    Mons, Hainaut, Belgium

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium

  • AZ Sint-Jan AV

    Bruges, West-Vlaanderen, Belgium

  • Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • Universidade Federal do Rio de Janeiro - UFRJ

    Rio de Janeiro, Brazil

  • Irmandade Da Santa Casa de Misericordia de Sao Paulo

    São Paulo, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, Brazil

  • Hospital Das Clinicas Da Universidade Federal de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto de Oncologia Do Parana

    Curitiba, Paraná, Brazil

  • Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil

  • Hospital de Clinicas de Passo Fundo

    Passo Fundo, Rio Grande do Sul, Brazil

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.